William Blair analyst Matt Phipps initiates coverage on Climb Bio (NASDAQ: CLYM) with a Outperform rating.The analyst comments "We are ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE